Mission & Story
Mission
To Make Personalized Medicine Accessible to All
Founding Story
Founded in 2014 by a small group of scientists from academia with the passion to 'turn genomics into action' and apply academic theories in clinical practice. Member of the Delta Group. Co-founded by Hua Chien Chen (CEO).
Clinical Focus
Medical conditions and clinical areas addressed by ACT Genomics.
Who It Serves
Milestones & Awards
Recent Milestones
FDA 510(k) clearance for ACTOnco® (January 2023). Majority stake acquired by Prenetics Global Limited (December 2022). ISO/IEC 27701:2019 certification (February 2024). ACTDrug® upgraded to 101-gene panel with 7-day turnaround (April 2026). ACTMonitor® Breast expanded to 10-gene panel (February 2026). Delta Electronics board approved proposal to acquire shareholdings (June 2025).
Awards & Recognition
Symbol of National Quality in Taiwan (2016). Frost & Sullivan Product Line Strategy Leadership Award in Molecular Diagnostics (2017). National Innovation Award in Taiwan (2018, 2019). Taiwan Bio Industry Organization Awards - Emerging Company of the Year (2019). Golden Torch Award - Annual Top 10 Enterprise in Taiwan (2019). Frost & Sullivan Best Practices Award (2021).
Key Partnerships
Social & Media
Latest Updates
ACT Genomics and mProbe Announces Strategic Integration of Proteomics to Elevate Precision Medicine in Asia
ACT Genomics and LSI Medience Sign MOU to form a Strategic Partnership and Collaborate in the Japanese Market
ACT Genomics and mProbe Announce Strategic Partnership to Advance Precision Medicine in Asia
Company Details
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingSecurity & Compliance
Official Sources
Similar Companies in this Market
View all 60 →
23andMe
23andMe uses AI to analyze genetic data and provide personalized health summaries, risk assessments, and wellness recommendations based on genomic insights.
2bPrecise
AI-powered precision medicine platform for personalized treatment recommendations and genomic analysis.
Adaptive Biotechnologies
Adaptive Biotechnologies uses AI and machine learning to decode the immune system and identify disease-specific immune signatures for diagnosis and personalized treatment.
Ambry Genetics
Ambry Genetics is a leading clinical genetic testing laboratory specializing in hereditary cancer, rare disease, cardiology, and neurology testing. The company provides advanced genetic testing solutions with paired DNA/RNA analysis and comprehensive patient support programs.
Ataraxis
Ataraxis develops AI-native precision medicine tools that predict patient outcomes and treatment response in oncology. Their flagship product, Ataraxis Breast, provides clinically validated prognostic and predictive tests for breast cancer using multi-modal AI analysis of pathology images and clinical data.
Avenda Health
Avenda Health develops Unfold AI, an FDA-cleared artificial intelligence platform that creates 3D cancer estimation maps for prostate cancer. The technology analyzes standard-of-care data (MRI, biopsy, pathology, PSA) to visualize cancer location and extent, helping physicians make more informed treatment decisions and improve patient outcomes.
Base Genomics
Base Genomics appears to be a company in the Precision Medicine & Genomics space, but the scraped website content is empty or inaccessible, preventing detailed analysis of their offerings and target market.
Beacon Biosignals
Beacon Biosignals is a precision neuroscience platform that uses AI-powered technology to accelerate drug development and power home sleep testing diagnostics. The company collects, integrates, and analyzes EEG data across the full drug development lifecycle.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.